Expression of Vascular Endothelial Growth Factor Gene and Its Receptor (flt-1) Gene in Urinary Bladder Cancer.

Sato, Kazunari; Sasaki, Ryuta; Ogura, Yasunobu; Shimoda, Naotake; Togashi, Hisafumi; Terada, Kunihiko; Sugiyama, Toshihiro; Kakinuma, Hiroaki; Ogawa, Osamu; Kato, Takumi

doi:10.1620/tjem.185.173

Cited by 35 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present work, we explored by Northern blotting the VEGF-A mRNA expression in bladder tumors and analysed its relationship to the tumor stage and grade. As already reported (18,30), we displayed two VEGF-A transcripts of 5.2, 4.5 kb. On the contrary, we did not reveal the 3.7 kb transcript and we detected for the first time to our knowledge in bladder cancer samples a shorter transcript of 1.7 kb in length.…”

Section: Discussionsupporting

confidence: 86%

“…But finally, few studies have been performed on VEGF-A expression at the mRNA level in bladder cancer. From 30 patients with TCC of the urinary bladder, Sato et al (18) detected by Northern blot hybridization analysis three VEGF-A transcripts of 5.5 kb, 4.4 kb and 3.7 kb. The same transcripts have also been observed in human colon carcinoma cells (30).…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, conflicting studies have questioned the prognostic value of VEGF-A within the tumor. O'Brien et al (17) reported that an average expression level of the vegf-A gene in non-invasive (pTa and pT1) tumors was higher than in invasive tumors and in normal tissue while Sato et al (18) demonstrated that invasive TCC expressed more vegf-A gene than non-invasive TCC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. The present investigation was conducted first to determine whether correlation exists between VEGF-A and -B mRNA levels and clinicopathological parameters and to assess their prognostic value in bladder cancer, then to clarify the expression level and biological significance of VEGF-A isoforms. Total RNA was isolated from 37 specimens of bladder cancer. Northern blot analysis revealed that VEGF-B mRNA was not expressed either in normal urothelium or in bladder cancer and detected three VEGF-A transcripts of 5.2, 4.5 and 1.7 kb in length, respectively. The VEGF-A transcript levels were greater in cancer tissues than in normal urothelium. They were significantly higher in pT2-T4 than in pTa and pT1 urothelial tumors and thus, were correlated to the pathologic stage. Contrary to the 4.5 kb transcript, elevated expression of the 5.2 and 1.7 kb transcripts was correlated with the histologic grade and the presence of carcinoma in situ. Patients with higher VEGF-A mRNA levels had a significantly shorter survival without progression compared to those with lower levels. Three VEGF-A splice variants were detected by Southern blotting namely, VEGF121, 165 and 189. The expression intensity of each isoform was evaluated by quantitative real-time RT-PCR in 20 new fresh frozen recent tumors. VEGF121 and VEGF165 were expressed at the similar level. On the contrary, they were significantly more expressed than VEGF189 (p<0.05). The three isoforms were higher expressed in pT2 bladder cancers than in pTa tumors (p<0.05). There was only a significant correlation between the increased expression level of VEGF121 and 165 and the histological grade of the lesion (p<0.05). To conclude, VEGF-A mRNA level is a potential prognostic indicator of progression in bladder cancer as well as the expression level of the different VEGF-A splice variants.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet¹

2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In previous studies the prognostic value of VEGF in patients with different malignancies, e.g. malignancies of the female tract (Abulafia et al, 1999;Hazelton et al, 1999;Santin et al, 1999;Tjalma et al, 2000;Boss et al, 2001), prostate (Bok et al, 2001), colon (Cascinu et al, 2001), urinary bladder (Sato et al, 1998;Crew et al, 1999), renal cell (Nicol et al, 1997) and thyroid gland (Lennard et al, 2000) has been investigated.…”

mentioning

confidence: 99%

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy

et al. 2002

View full text Add to dashboard Cite

The growth and metastasising capacity of solid tumours are dependent on angiogenesis. Vascular endothelial growth factor is a mediator of angiogenesis. In this study we investigated whether vascular endothelial growth factor is associated with the natural course of the disease in primary invasive breast cancer. In 574 tumours of patients with node-negative invasive breast cancer the cytosolic levels of vascular endothelial growth factor were measured using a quantitative enzyme-linked immunosorbent assay. These patients did not receive adjuvant systemic therapy and were followed for a median follow-up time of 61 months (range 2 -155 months) after the primary diagnosis. Correlations with well-known prognostic factors, and univariate and multivariate survival analyses were performed. Vascular endothelial growth factor level was positively associated with age and tumour size (P=0.042 and P=0.029, respectively). In addition, vascular endothelial growth factor level was inversely, but weakly correlated with progesterone receptor levels (PgR) (r s =70.090, P=0.035). A high vascular endothelial growth factor level (equal or above the median level of 0.53 ng mg 71 protein) predicted a reduced relapse-free survival and overall survival in the univariate survival rate analysis (for both P=0.005). In the multivariate analysis as well, vascular endothelial growth factor showed to be an independent predictor of poor relapse-free survival and overall survival (P=0.045 and P=0.029, respectively), in addition to age, tumour size and PgR. The results show that cytosolic levels of vascular endothelial growth factor in tumour tissue samples are independently indicative of prognosis for patients with node-negative breast cancer who were not treated with adjuvant systemic therapy. This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression.

show abstract

“…Increased expression of VEGF can promote tumor angiogenesis, which supplies oxygen and nutrients for tumor cell growth and rapid proliferation leading to malignant progression. Sato et al (1998) found that positive expression of VEGF in patients with recurrent BTCC is significantly higher than that of VEGF in patients without recurrence within 2 postoperative years. The authors confirmed that VEGF can be regarded as an index for assessing malignancy, invasion, and recurrence of bladder cancer.…”

Section: Discussionmentioning

confidence: 86%

Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma

Sun¹,

Xuan²,

Qa³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Survivin and vascular endothelial growth factor (VEGF) are newly discovered tumor markers closely correlated with bladder cancer. We analyzed the expression of survivin and VEGF in paraffin-embedded tumor tissues from 78 patients with bladder transitional cell carcinoma (BTCC) using an immunohistochemistry method. Normal bladder mucosae from 10 non-BTCC cases were also included as a control group. All patients were closely followed up for tumor recurrence after undergoing transurethral resection of bladder tumor procedures. The positive expression rates of survivin and VEGF in superficial BTCC were 66.7% (52/78) and 69.2% (54/78), respectively, which were significantly higher than those in the control group, 0% (0/10). A positive correlation was found between survivin and VEGF expression (r = 0.283, P < 0.01). Thirty-two of 78 patients (41.0%) displayed recurrence during follow-up (median: 47; range: 7-62 months). The tumor recurrence rate in survivin(+) patients was 53.8% (28/52), which was significantly higher than that in survivin(-) patients [15.4% (4/26); P < 0.05]. The recurrence rate in VEGF(+)/ VEGF(-) patients was 50.0% (27/54) and 20.8% (5/24), respectively (P < 0.05). The sensitivity for predicting the relapse of superficial BTCC was 87.5% in the survivin(+) group, 84.4% in the VEGF(+) group, and 78.1% in the survivin(+)/VEGF(+) group, and the specificity was 47.8, 41.3, and 65.2%, respectively. Survivin and VEGF interact and jointly regulate the biological behavior of bladder cancer. Our results suggest that overexpression of survivin and VEGF accompany a higher risk of BTCC recurrence, making survivin and VEGF biomarkers for predicting the relapse of bladder cancer.

show abstract

Expression of Vascular Endothelial Growth Factor Gene and Its Receptor (flt-1) Gene in Urinary Bladder Cancer.

Cited by 35 publications

References 19 publications

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy

Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma

Contact Info

Product

Resources

About